Anadis to commercialise BioGard
Thursday, 04 September, 2008
Anadis [ASX: ANX] is to begin commercialisation of BioGard, a treatment designed to maintain gastrointestinal and immune system health.
The treatment, aimed at people undergoing antiretroviral therapy for HIV/AIDS, will be marketed as medical food.
BioGard's active ingredient is a formulation of antigen-targeted Bovine Clostrum Powder (BCP). The cows from which the powder is sourced will be vaccinated with a mixture of lipopolysaccarides implicated as key drivers of AIDS pathogenesis.
It will at first be made available in tablet form, sold over-the-counter but intended for use under medical supervision.
The product's ingredients and manufacturing process has been approved by the TGA.
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
Low-dose drug prevents diabetes progression in young people
A low dose of the immunomodulatory drug anti-thymocyte globulin (ATG) appears safe and effective...
